Annabel García‐León

Conjugation strategy shapes antitumor efficacy and enables dose-sparing in non-antibody protein nanoconjugates

Ariana Rueda, Annabel García‐León, Lourdes A. Arena, Julián I. Mendoza et autres

Precision targeting is a hot topic in cancer nanomedicine, as conventional chemotherapies cause systemic toxicities, creating an urgent need for more selective treatments. Although antibody-drug conjugates (ADCs) are the current gold standard in targeted therapy, their clinical performance remains limited. As an …

es (code pays fourni par la source)

Precision targeting of CXCR4+ leukemia cells by a humanized MMAE-nanoconjugate in an AML mouse model

Annabel García‐León, Julián I. Mendoza, Ariana Rueda, Lorena Alba‐Castellón et autres

Acute myeloid leukemia (AML) presents major clinical challenges due to chemoresistance and high relapse rates, primarily driven by therapy-resistant leukemic stem cells (LSCs) within the bone marrow. To address this issue, we developed T22-HSNBT-H6-MMAE, a novel humanized nanoconjugate designed to target CXCR4 …

es (code pays fourni par la source)

Paradoxical cell targeting of calreticulin-empowered, protein-only nanoparticles

Eloi Parladé, Annabel García‐León, Eric Voltà‐Durán, Ugutz Unzueta et autres

Surface-exposed calreticulin (CRT) serves as a crucial cell damage-associated molecular pattern for immunogenic apoptosis, by generating an “eat me” signal to macrophages. Aiming at precision immunotherapies we intended to artificially label tumoral cells in vivo with a recombinant CRT, in a targeted …

es (code pays fourni par la source)

T22-PE24-H6 Nanotoxin Selectively Kills CXCR4-High Expressing AML Patient Cells In Vitro and Potently Blocks Dissemination In Vivo

Yáiza Núñez, Annabel García‐León, Aïda Falgàs, Naroa Serna et autres

Despite advances in the development of targeted therapies for acute myeloid leukemia (AML), most patients relapse. For that reason, it is still necessary to develop novel therapies that improve treatment effectiveness and overcome drug resistance. We developed T22-PE24-H6, a protein nanoparticle that …

es (code pays fourni par la source)

Potent Anticancer Activity of CXCR4-Targeted Nanostructured Toxins in Aggressive Endometrial Cancer Models

Esperanza Medina-Gutiérrez, Annabel García‐León, Alberto Gallardo, Patricia Álamo et autres

Patients with advanced endometrial cancer (EC) show poor outcomes. Thus, the development of new therapeutic approaches to prevent metastasis development in high-risk patients is an unmet need. CXCR4 is overexpressed in EC tumor tissue, epitomizing an unexploited therapeutic target for this malignancy. …

es (code pays fourni par la source)

A diphtheria toxin-based nanoparticle achieves specific cytotoxic effect on CXCR4+ lymphoma cells without toxicity in immunocompromised and immunocompetent mice

Aïda Falgàs, Annabel García‐León, Yáiza Núñez, Naroa Serna et autres

High rates of relapsed and refractory diffuse large B-cell lymphoma (DLBCL) patients and life-threatening side effects associated with immunochemotherapy make an urgent need to develop new therapies for DLBCL patients. Immunotoxins seem very potent anticancer therapies but their use is limited because …

es (code pays fourni par la source)

Raw data to support the manuscript "Engineering non-antibody human proteins as efficient scaffolds for selective, receptor-targeted drug delivery"

Naroa Serna, Víctor Pallarès, Ugutz Unzueta, Annabel García‐León et autres

Raw data of a set of experiments aimed to explore the suitability of different human proteins as scaffold for targeted nanocarriers. Serna, Naroa; Pallarès, Victor; Unzueta Elorza, Ugutz; García-León, Annabel; Voltà-Durán, Eric; Sánchez Chardi, Alejandro; Parladé Molist, Eloi; Rueda, Ariana; Casanova Rigat, …

es (code pays fourni par la source)

Engineering non-antibody human proteins as efficient scaffolds for selective, receptor-targeted drug delivery

Naroa Serna, Víctor Pallarès, Ugutz Unzueta, Annabel García‐León et autres

es (code pays fourni par la source)

Time-Prolonged Release of Tumor-Targeted Protein–MMAE Nanoconjugates from Implantable Hybrid Materials

Naroa Serna, Aïda Falgàs, Annabel García‐León, Ugutz Unzueta et autres

The sustained release of small, tumor-targeted cytotoxic drugs is an unmet need in cancer therapies, which usually rely on punctual administration regimens of non-targeted drugs. Here, we have developed a novel concept of protein–drug nanoconjugates, which are packaged as slow-releasing chemically hybrid …

es (code pays fourni par la source)

A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model

Víctor Pallarès, Ugutz Unzueta, Aïda Falgàs, Anna Maria Aviñó et autres

Current therapy in acute myeloid leukemia (AML) is based on chemotherapeutic drugs administered at high doses, lacking targeting selectivity and displaying poor therapeutic index because of severe adverse effects. Here, we develop a novel nanoconjugate that combines a self-assembled, multivalent protein nanoparticle, …

es (code pays fourni par la source)

LDL receptor regulates the reverse transport of macrophage-derived unesterified cholesterol via concerted action of the HDL-LDL axis

Lídia Cedó, Jari Metso, David Santos, Annabel García‐León et autres

es, fi (code pays fourni par la source)

LDL Receptor Regulates the Reverse Transport of Macrophage-Derived Unesterified Cholesterol via Concerted Action of the HDL-LDL Axis

Lídia Cedó, Jari Metso, David Santos, Annabel García‐León et autres

RATIONALE: The HDL (high-density lipoprotein)-mediated stimulation of cellular cholesterol efflux initiates macrophage-specific reverse cholesterol transport (m-RCT), which ends in the fecal excretion of macrophage-derived unesterified cholesterol (UC). Early studies established that LDL (low-density lipoprotein) particles could act as efficient intermediate acceptors of …

es, fi (code pays fourni par la source)